Trial Profile
A Multicenter, Randomized, Double-blind, Placebo- Controlled, Cross-over, Proof of Concept Study Comparing the Effects of Both Single Dose and Repeated Dosing Treatment for 2 Weeks of BGG492 in Patients With Chronic Subjective Tinnitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Mar 2017
Price :
$35
*
At a glance
- Drugs Selurampanel (Primary)
- Indications Tinnitus
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis
- 16 Jul 2014 New trial record